The estimated Net Worth of Pauline Mc Gowan is at least $4.17 Tausend dollars as of 14 December 2015. Pauline Gowan owns over 498 units of Concert Pharmaceuticals Inc stock worth over $4,168 and over the last 10 years Pauline sold CNCE stock worth over $0.
Pauline has made over 7 trades of the Concert Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Pauline exercised 498 units of CNCE stock worth $1,743 on 14 December 2015.
The largest trade Pauline's ever made was exercising 22,122 units of Concert Pharmaceuticals Inc stock on 10 March 2015 worth over $43,802. On average, Pauline trades about 3,058 units every 28 days since 2014. As of 14 December 2015 Pauline still owns at least 498 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Pauline Gowan stock trades at the bottom of the page.
Pauline's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, SUITE 500, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... und Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: